Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.

Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.

The brokered deal will broaden DiaSorin’s offerings in the rapidly growing liquid diagnostics market, while also providing Luminex furthered access to markets outside of the US.

The buyout will broaden DiaSorin’s positioning in the fast-growing molecular diagnostics space and expand Luminex’s foothold outside the US.